Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Amylx Pharmaceuticals Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.44 (market cap $2.14B), while Amylx Pharmaceuticals Inc trades at $23.89 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMC | AMLX | |
|---|---|---|
Market Cap | $2.14B | $2.64B |
Sector | Media | Health |
52-Week High | $3.15 | $24.19 |
52-Week Low | $0.95 | $7.82 |
Enterprise Value | $9.08B | $2.39B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).
The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
